Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

Inclusion Criteria:

* Adults over age 18 years of age with a life expectancy of at least 3 months.
* Histologically or cytologically confirmed stage IIIB or stage IV non squamous non-small-cell lung cancer (NSCLC) who have progressed after 1 chemotherapy regimen.
* Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST, Version 1.1) on cross-sectional imaging that is at least 2 cm in longest diameter.
* Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.
* Adequate hematologic, renal, and hepatic function.
* PT/INR ≤ 1.5 × ULN; aPTT time ≤ 1.5 × ULN.
* New York Heart Association classification I or II

Exclusion Criteria:

* Squamous, small cell, or mixed histology.
* Known history of bleeding diathesis or coagulopathy.
* Cavitary tumors or tumors invading or abutting large blood vessels.
* Bleeding: Clinically significant bleeding such as gross hematuria, GI bleeding and hemoptysis within 12 months of Screening.
* Venous thromboembolic events within 6 months of screening.
* Ongoing therapy with oral or parenteral anticoagulants.
* Concurrent estrogens, anti-estrogens or progesterone compounds.
* Radiotherapy within 2 weeks or major surgery within 4 weeks preceding Study Day 1.
* Symptomatic or clinically active brain metastases.
* Symptomatic coronary artery disease, cerebrovascular accident, transient ischemic attack, myocardial infarction or unstable angina pectoris within 6 months of screening.
* Grade 2 or higher peripheral neuropathy